A phase 1/2 trial of SF0166 eye drops for wet age-related macular degeneration has shown positive top-line results, according to a press release from SciFluor Life Sciences.
The safety and tolerability, as well as preliminary efficacy, of SF0166 were evaluated in the 28-day double-masked study of 42 patients.
Subjects were randomized to self-administer an eye drop containing either a 2.5% or 5% solution of SF0166 twice a day, the release said. No serious drug-related events were observed during the 28-day treatment or 28-day follow-up; five subjects showed mild or moderate (Read more...)
Uncategorized